Eli Lilly CDR (CAD Hedged)

IXICO has deepened its collaboration with the Global Alzheimer's Platform Foundation through an agreement securing full data usage rights to the Bio-Hermes-002 study, one of the most prominent global studies in Alzheimer's disease research.

Eli Lilly's FORAGER-1 Phase 1 study is evaluating LOXO-435 (LY3866288) as both monotherapy and combination treatment for locally advanced or metastatic solid tumors with FGFR3 gene alterations.

Livzon Pharmaceutical's LZM012, the first domestic dual-target IL-17A/F monoclonal antibody, achieved superior efficacy compared to Secukinumab in a Phase III trial for moderate to severe plaque psoriasis.

Omega Funds successfully closed its eighth fund with $647 million in capital commitments, exceeding its $600 million target despite challenging fundraising conditions.

Bristol Myers Squibb and Pfizer announced a new direct-to-patient purchasing option for Eliquis (apixaban) through their Eliquis 360 Support program, offering eligible patients a cash price more than 40% below the current $606 list price.

Up to 3,500 FDA staffers received termination notices following a Supreme Court ruling that found the government's HHS overhaul to be lawful.

Hengrui Pharma and Kailera Therapeutics' dual-acting obesity drug HRS9531 demonstrated 18% weight loss in a Phase 3 trial in China, significantly outperforming placebo by 16%.

Illimis Therapeutics closed a $42 million Series B funding round with participation from 18 investors to accelerate development of its GAIA platform targeting Alzheimer's disease and immune disorders.

Cipla is preparing to enter India's weight management segment to address rising demand for effective obesity solutions, as announced by CEO Umang Vohra in the company's 2024-25 annual report.

A new analysis from the EMPA-KIDNEY trial demonstrates that empagliflozin is cost-effective for chronic kidney disease treatment, improving quality-adjusted life years while reducing healthcare costs.